[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339603-105":59,"doc-detail-339603-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antineoplastic-effect-of-alk-inhibitor-crizotinib-in-primary-human-anaplastic-thyroid-cancer-cells-with-strnalk-fusion-in-vitro","Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro","","Anaplastic thyroid cancer (ATC) is among the most lethal human malignancies and accounts for less than 2% of thyroid carcinomas. The study targets ALK rearrangements as drivers of tumor growth and assesses crizotinib, an oral tyrosine kinase inhibitor of ALK, MET, and ROS1. Primary human ATC cells (pATCs) with STRN–ALK fusion were generated in vitro from thyroid surgical samples. Crizotinib suppressed proliferation, migration, and invasion while increasing apoptosis, especially in STRN–ALK–positive cultures, and also inhibited AF cell growth. These preclinical findings support future clinical evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antineoplastic-effect-of-alk-inhibitor-crizotinib-in-primary-human-anaplastic-thyroid-cancer-cells-with-strnalk-fusion-in-vitro/339603/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antineoplastic-effect-of-alk-inhibitor-crizotinib-in-primary-human-anaplastic-thyroid-cancer-cells-with-strnalk-fusion-in-vitro/339603.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study on crizotinib in ATC cells?","Question",{"text":112,"@type":113},"To generate primary human ATC cells with STRN–ALK fusion in vitro and evaluate the in vitro antineoplastic activity of crizotinib.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the primary human ATC cells obtained and what fusion status was found?",{"text":117,"@type":113},"Thyroid surgical samples were collected from 12 ATC patients and 6 controls, yielding 10/12 pATC cultures, including 2 cultures with STRN–ALK fusion (17%).",{"name":119,"@type":110,"acceptedAnswer":120},"What cellular effects did crizotinib produce in the tested cultures?",{"text":121,"@type":113},"Crizotinib inhibited proliferation, migration, and invasion and increased apoptosis, with stronger effects particularly in cultures containing STRN–ALK fusion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339603,1790863584,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Article  \nAntineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro  \nSilvia Martina Ferrari 1,*, Francesca Ragusa 2, Giusy Elia 2, Valeria Mazzi 2, Eugenia Balestri 2, Chiara Botrini 2, Licia Rugani 2, Armando Patrizio 3, Simona Piaggi 4, Concettina La Motta 5, Salvatore Ulisse 6, Camilla Virili 7, Alessandro Antonelli 2 and Poupak Fallahi 4  \nCitation: Ferrari, S.M.; Ragusa, F.; Elia, G.; Mazzi, V.; Balestri, E.; Botrini, C.; Rugani, L.; Patrizio, A.; Piaggi, S.; La Motta, C.; et al. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. Int. J. Mol. Sci. 2024, 25, 6734 . [https://doi.org/10.3390/ijms25126734](https://doi.org/10.3390/ijms25126734)  \nAcademic Editor: Evgeny Imyanitov  \nReceived: 10 May 2024  \nRevised: 7 June 2024  \nAccepted: 17 June 2024  \nPublished: 19 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy  \n2 Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa,  \n56126 Pisa, Italy; [francesca.ragusa@phd.unipi.it](francesca.ragusa@phd.unipi.it) (F.R.); [giusy.elia@phd.unipi.it](giusy.elia@phd.unipi.it) (G.E.); [mazzivaleria@gmail.com](mazzivaleria@gmail.com) (V.M.); [eugenia.balestri@phd.unipi.it](eugenia.balestri@phd.unipi.it) (E.B.); [chiara.botrini@gmail.com](chiara.botrini@gmail.com) (C.B.); [licia.rugani99@gmail.com](licia.rugani99@gmail.com) (L.R.); [alessandro.antonelli@unipi.it](alessandro.antonelli@unipi.it) (A.A.)  \n3 Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy; [armandopatrizio125@gmail.com](armandopatrizio125@gmail.com)  \n4 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; [simona.piaggi@unipi.it](simona.piaggi@unipi.it) (S.P.); [poupak.fallahi@unipi.it](poupak.fallahi@unipi.it) (P.F.)  \n5 Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; [concettina.lamotta@unipi.it](concettina.lamotta@unipi.it)  \n[6](6 Department of Surgery)[ Department of Surgery](6 Department of Surgery),“Sapienza” University of Rome, 00161 Rome, Italy; salvatore.ulisse@uniroma1.it  \n7 Department of Medico-Surgical Sciences and Biotechnologies, Endocrinology Section,“Sapienza” University of Rome, 04100 Latina, Italy; [camilla.virili@uniroma1.it](camilla.virili@uniroma1.it)  \n* Correspondence: [silvia.ferrari@unipi.it](silvia.ferrari@unipi.it)  \nAbstract: Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and represents \u003C2% of thyroid carcinomas. A therapeutic target for ATC is represented by anaplastic lymphoma kinase (ALK) rearrangements, involved in tumor growth. Crizotinib is an oral small-molecule tyrosine kinase inhibitor of the ALK, MET, and ROS1 kinases, approved in ALK-positive non-small cell lung cancer. Until now, the effect of crizotinib in “primary human ATC cells”(pATCs) with transforming striatin (STRN)–ALK fusion has not been reported in the literature. In this study, we aimed to obtain pATCs with STRN–ALK in vitro and evaluate the in vitro antineoplastic action of crizotinib. Thyroid surgical samples were obtained from 12 ATC patients and 6 controls (who had undergone parathyroidectomy) . A total of 10/12 pATC cultures were obtained, 2 of which with transforming STRN–ALK fusion (17%) . Crizotinib inhibited proliferation, migration, and invasion and increased apoptosis in 3/10 pATC cultures (2 of which with/1 without STRN–ALK), particularly in those with STRN–ALK. Moreover, cri","cbCailEeQYg4L3hJ","https://ap.wps.com/l/cbCailEeQYg4L3hJ","pdf",2286229,17,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is the main purpose of the study on crizotinib in ATC cells?\",\"answer\":\"To generate primary human ATC cells with STRN–ALK fusion in vitro and evaluate the in vitro antineoplastic activity of crizotinib.\"},{\"question\":\"How were the primary human ATC cells obtained and what fusion status was found?\",\"answer\":\"Thyroid surgical samples were collected from 12 ATC patients and 6 controls, yielding 10/12 pATC cultures, including 2 cultures with STRN–ALK fusion (17%).\"},{\"question\":\"What cellular effects did crizotinib produce in the tested cultures?\",\"answer\":\"Crizotinib inhibited proliferation, migration, and invasion and increased apoptosis, with stronger effects particularly in cultures containing STRN–ALK fusion.\"}]","Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro | PDF",1790031201,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/551dc2c01067ca8c0af5ae648d8834af.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddb24f98cedef4d66f41993e4fe46775.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73bfdbd9b1e47b5028446599c6aaf54a.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a9f913a162c5cab8ae9e22f49a3f241.webp",980,1385]